Cargando…
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites
Tolvaptan is a new drug used for treating ascites induced by liver cirrhosis, and it is covered by health insurance in Japan. In the present report, we describe the case of a 74-year-old man with type C liver cirrhosis and refractory ascites. He was receiving furosemide and spironolactone daily, but...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Japan
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331598/ https://www.ncbi.nlm.nih.gov/pubmed/25475138 http://dx.doi.org/10.1007/s12328-014-0545-8 |